[go: up one dir, main page]

WO2009047904A1 - ウラシル誘導体を有効成分とする炎症性腸疾患治療薬 - Google Patents

ウラシル誘導体を有効成分とする炎症性腸疾患治療薬 Download PDF

Info

Publication number
WO2009047904A1
WO2009047904A1 PCT/JP2008/002861 JP2008002861W WO2009047904A1 WO 2009047904 A1 WO2009047904 A1 WO 2009047904A1 JP 2008002861 W JP2008002861 W JP 2008002861W WO 2009047904 A1 WO2009047904 A1 WO 2009047904A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
inflammatory bowel
bowel disease
active ingredient
uracil derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/002861
Other languages
English (en)
French (fr)
Inventor
Kazuki Sakamoto
Fumio Nakagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to AU2008310481A priority Critical patent/AU2008310481B2/en
Priority to CA2702023A priority patent/CA2702023A1/en
Priority to EP08838057A priority patent/EP2204175A4/en
Priority to JP2009536927A priority patent/JP5380295B2/ja
Priority to US12/682,599 priority patent/US8188105B2/en
Priority to CN2008801109305A priority patent/CN101820880B/zh
Publication of WO2009047904A1 publication Critical patent/WO2009047904A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

　炎症性腸疾患治療薬の提供。 　一般式（１）で表されるウラシル誘導体又はその薬学的に許容される塩を有効成分とする炎症性腸疾患治療薬。
PCT/JP2008/002861 2007-10-11 2008-10-10 ウラシル誘導体を有効成分とする炎症性腸疾患治療薬 Ceased WO2009047904A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2008310481A AU2008310481B2 (en) 2007-10-11 2008-10-10 Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient
CA2702023A CA2702023A1 (en) 2007-10-11 2008-10-10 Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient
EP08838057A EP2204175A4 (en) 2007-10-11 2008-10-10 THERAPEUTIC AGAINST INFLAMMATORY DISEASES MT URACIL DERIVATIVES AS ACTIVE SUBSTANCE
JP2009536927A JP5380295B2 (ja) 2007-10-11 2008-10-10 ウラシル誘導体を有効成分とする炎症性腸疾患治療薬
US12/682,599 US8188105B2 (en) 2007-10-11 2008-10-10 Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient
CN2008801109305A CN101820880B (zh) 2007-10-11 2008-10-10 以尿嘧啶衍生物为有效成分的炎症性肠疾病的治疗药

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007265339 2007-10-11
JP2007-265339 2007-10-11

Publications (1)

Publication Number Publication Date
WO2009047904A1 true WO2009047904A1 (ja) 2009-04-16

Family

ID=40549056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002861 Ceased WO2009047904A1 (ja) 2007-10-11 2008-10-10 ウラシル誘導体を有効成分とする炎症性腸疾患治療薬

Country Status (9)

Country Link
US (1) US8188105B2 (ja)
EP (1) EP2204175A4 (ja)
JP (1) JP5380295B2 (ja)
KR (1) KR20100082835A (ja)
CN (1) CN101820880B (ja)
AU (1) AU2008310481B2 (ja)
CA (1) CA2702023A1 (ja)
TW (1) TWI429439B (ja)
WO (1) WO2009047904A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019112383A1 (ko) * 2017-12-08 2019-06-13 윤주석 금속 미네랄 디아미네이트 및 이의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030346A1 (en) 1995-03-29 1996-10-03 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
WO1998013045A1 (en) 1996-09-24 1998-04-02 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
JP2000273044A (ja) 1999-03-23 2000-10-03 Taiho Yakuhin Kogyo Kk 副作用軽減剤
WO2007122812A1 (ja) * 2006-04-13 2007-11-01 Taiho Pharmaceutical Co., Ltd. 炎症性腸疾患治療薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037674A1 (en) 1996-04-05 1997-10-16 Kirin Beer Kabushiki Kaisha Substance originating in germinating seeds of gramineous plant and containing proteins and insoluble dietary fibers and use thereof
JP4110347B2 (ja) * 1999-11-05 2008-07-02 大鵬薬品工業株式会社 抗ｈｉｖ剤
US20070275988A1 (en) * 2003-09-05 2007-11-29 Schramm Vern L Transition state structure and inhibitors of thymidine phosphorylases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030346A1 (en) 1995-03-29 1996-10-03 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
WO1998013045A1 (en) 1996-09-24 1998-04-02 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
JP2000273044A (ja) 1999-03-23 2000-10-03 Taiho Yakuhin Kogyo Kk 副作用軽減剤
WO2007122812A1 (ja) * 2006-04-13 2007-11-01 Taiho Pharmaceutical Co., Ltd. 炎症性腸疾患治療薬

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, vol. 117, 1999, pages 761
N. ENGL. J. MED., vol. 337, 1997, pages 1029
PEDIATRIC RESEARCH, vol. 53, no. 1, 2003, pages 143 - 147
SAITO, S. ET AL.: "Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease", J GASTROENTEROL, vol. 38, no. 3, 2003, pages 229 - 37, XP008133005 *
See also references of EP2204175A4 *

Also Published As

Publication number Publication date
CN101820880B (zh) 2012-11-14
AU2008310481B2 (en) 2013-05-23
US20100222372A1 (en) 2010-09-02
KR20100082835A (ko) 2010-07-20
TWI429439B (zh) 2014-03-11
CN101820880A (zh) 2010-09-01
AU2008310481A1 (en) 2009-04-16
US8188105B2 (en) 2012-05-29
EP2204175A4 (en) 2012-02-29
JPWO2009047904A1 (ja) 2011-02-17
TW200918067A (en) 2009-05-01
CA2702023A1 (en) 2009-04-16
EP2204175A1 (en) 2010-07-07
JP5380295B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
TW200728307A (en) Novel spirochromanone derivatives
WO2007117465A3 (en) Indazole compounds
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2007150026A3 (en) Purinone derivatives as hm74a agonists
WO2008096841A1 (ja) 二量化シクロ誘導体
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
EP2196206B8 (en) Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
WO2007095039A3 (en) Pharmaceutical formulations
WO2008155666A3 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
WO2009055289A3 (en) Therapeutic substituted lactams
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2008146774A1 (ja) テトラヒドロイソキノリン-1-オン誘導体またはその塩
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2008093838A1 (ja) スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
WO2007112913A3 (en) Benzimidazole derivatives
WO2008153129A1 (ja) 尿酸値低下剤
PL1932522T3 (pl) Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880110930.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08838057

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009536927

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20107007633

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2702023

Country of ref document: CA

Ref document number: 2008838057

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008310481

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12682599

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008310481

Country of ref document: AU

Date of ref document: 20081010

Kind code of ref document: A